Change in baseline characteristics over 20 years of adults with growth hormone (GH) deficiency on GH replacement therapy

in European Journal of Endocrinology

Correspondence should be addressed to C Höybye; Email: charlotte.hoybye@sll.se
Restricted access

Objective

Clinical observations over time of adults with growth hormone (GH) deficiency (GHD) have indicated a shift in patient characteristics at diagnosis. The objective of this study was to compare baseline characteristics of patients diagnosed with adult-onset GHD naive to GH replacement during three study periods (1994–1999 (P1), 2000–2004 (P2), and 2005–2012 (P3)) using the KIMS (Pfizer’s International Metabolic) database.

Methods

Data were retrieved for a total of 6069 patients with adult-onset GHD from six countries (Belgium, Germany, Netherlands, Spain, Sweden, and UK): P1 (n = 1705), P2 (n = 2397), and P3 (n = 1967).

Results

The proportions of patients with pituitary/hypothalamic tumors and patients with multiple pituitary hormone deficiencies decreased per entry year period, while the proportions with hypertension and diabetes increased. The lag time from diagnosis of pituitary disease to start of GH treatment decreased by 2.9 years over the entry year periods. IGF-1 increased by 0.1 standard deviation score per entry year period. Maximum GH following various stimulation tests, BMI, and waist circumference increased. The use of radiotherapy, glucocorticoid replacement doses, and the proportion of women >50 years on estrogen replacement therapy decreased. The effects of 1 year of GH replacement were similar over the entry year periods despite changes in the patients’ baseline characteristics. An expected increase in fasting blood glucose was seen after 1 year of GH treatment.

Conclusions

The degree of confirmed GHD became less pronounced and more patients with co-morbidities and diabetes were considered for GH replacement therapy, possibly reflecting increased knowledge and confidence in GH therapy gained with time.

 

     European Society of Endocrinology

All Time Past Year Past 30 Days
Abstract Views 110 110 110
Full Text Views 15 15 15
PDF Downloads 14 14 14
  • 1

    BengtssonBAEdénSLönnLKvistHStoklandALindstedtGBosaeusITölliJSjöströmLIsakssonOG. Treatment of adults with growth hormone (GH) deficiency with recombinant human GH. Journal of Clinical Endocrinology and Metabolism 1993 309–317. (https://doi.org/10.1210/jcem.76.2.8432773)

    • Search Google Scholar
    • Export Citation
  • 2

    JørgensenJOPedersenSAThuesenLJørgensenJIngemann-HansenTSkakkebaekNEChristiansenJS. Beneficial effects of growth hormone treatment in GH-deficient adults. Lancet 1989 1221–1225. (https://doi.org/10.1016/s0140-6736(89)92328-3)

    • Search Google Scholar
    • Export Citation
  • 3

    SalomonFCuneoRCHespRSönksenPH. The effects of treatment with recombinant human growth hormone on body composition and metabolism in adults with growth hormone deficiency. New England Journal of Medicine 1989 1797–1803. (https://doi.org/10.1056/NEJM198912283212605)

    • Search Google Scholar
    • Export Citation
  • 4

    de BoerHBlokGJVan der VeenEA. Clinical aspects of growth hormone deficiency in adults. Endocrine Reviews 1995 63–86. (https://doi.org/10.1210/edrv-16-1-63)

    • Search Google Scholar
    • Export Citation
  • 5

    CarrollPVChristERBengtssonBACarlssonLChristiansenJSClemmonsDHintzRHoKLaronZSizonenkoP et al. Growth hormone deficiency in adulthood and the effects of growth hormone replacement: a review. Growth Hormone Research Society Scientific Committee. Journal of Clinical Endocrinology and Metabolism 1998 382–395. (https://doi.org/10.1210/jcem.83.2.4594)

    • Search Google Scholar
    • Export Citation
  • 6

    VerhelstJAbsR. Long-term growth hormone replacement therapy in hypopituitary adults. Drugs 2002 2399–2412. (https://doi.org/10.2165/00003495-200262160-00006)

    • Search Google Scholar
    • Export Citation
  • 7

    RosénTBengtssonBA. Premature mortality due to cardiovascular disease in hypopituitarism. Lancet 1990 285–288. (https://doi.org/10.1016/0140-6736(90)91812-o)

    • Search Google Scholar
    • Export Citation
  • 8

    BülowBHagmarLMikoczyZNordströmCHErfurthEM. Increased cerebrovascular mortality in patients with hypopituitarism. Clinical Endocrinology 1997 75–81. (https://doi.org/10.1046/j.1365-2265.1997.d01-1749.x)

    • Search Google Scholar
    • Export Citation
  • 9

    GilchristFJMurrayRDShaletSM. The effect of long-term untreated growth hormone deficiency (GHD) and 9 years of GH replacement on the quality of life (QoL) of GH-deficient adults. Clinical Endocrinology 2002 363–370. (https://doi.org/10.1046/j.1365-2265.2002.01608.x)

    • Search Google Scholar
    • Export Citation
  • 10

    MonsonJP. Long-term experience with GH replacement therapy: efficacy and safety. European Journal of Endocrinology 2003 (Supplement 2) S9–S14. (https://doi.org/10.1530/eje.0.148s009)

    • Search Google Scholar
    • Export Citation
  • 11

    GötherströmGBengtssonBABosaeusIJohannssonGSvenssonJ. Ten-year GH replacement increases bone mineral density in hypopituitary patients with adult onset GH deficiency. European Journal of Endocrinology 2007 55–64. (https://doi.org/10.1530/eje.1.02317)

    • Search Google Scholar
    • Export Citation
  • 12

    FideleffHLBoqueteHRStalldeckerGGiaccioAVSobradoPGV. Comparative results of a 4-year study on cardiovascular parameters, lipid metabolism, body composition and bone mass between untreated and treated adult growth hormone deficient patients. Growth Hormone and IGF Research 2008 318–324. (https://doi.org/10.1016/j.ghir.2008.01.002)

    • Search Google Scholar
    • Export Citation
  • 13

    CenciMCConceiçãoFLSoarsDVSpinaLDBrasilRRLoboPMMichmacherEVaismanM. Impact of 5 years of growth hormone replacement therapy on cardiovascular risk factors in growth hormone-deficient adults. Metabolism: Clinical and Experimental 2008 121–129. (https://doi.org/10.1016/j.metabol.2007.08.015)

    • Search Google Scholar
    • Export Citation
  • 14

    ElbornssonMGötherströmGBosæusIBengtssonJohannssonGSvenssonJ. Fifteen years of GH replacement increases bone mineral density in hypopituitary patients with adult-onset GH deficiency. European Journal of Endocrinology 2012 787–795. (https://doi.org/10.1530/EJE-11-1072)

    • Search Google Scholar
    • Export Citation
  • 15

    Feldt-RasmussenUKloseM. Adult growth hormone deficiency clinical management. (available at: https://www.ncbi.nlm.nih.gov/books/NBK278943/). Accessed on 9 July 2019.

    • Search Google Scholar
    • Export Citation
  • 16

    BurmanPMattssonAFJohannssonGHöybyeCHolmerHDahlqvistPBerinderKEngströmBEEkmanBErfurthEM et al. Deaths among adult patients with hypopituitarism: hypocortisolism during acute stress, and de novo malignant brain tumors contribute to an increased mortality. Journal of Clinical Endocrinology and Metabolism 2013 1466–1475. (https://doi.org/10.1210/jc.2012-4059)

    • Search Google Scholar
    • Export Citation
  • 17

    GascoVProdamFGrottoliSMarzulloPLongobardiSGhigoEAimarettiG. Growth hormone therapy in adult growth hormone deficiency: a review of treatment schedules and the evidence for low starting doses. European Journal of Endocrinology 2013 R55–R66. (https://doi.org/10.1530/EJE-12-0563)

    • Search Google Scholar
    • Export Citation
  • 18

    ElbornssonMGötherströmGBosæusIBengtssonJohannssonGSvenssonJ. Fifteen years of GH replacement improves body composition and cardiovascular risk factors. European Journal of Endocrinology 2013 745–753. (https://doi.org/10.1530/EJE-12-1083)

    • Search Google Scholar
    • Export Citation
  • 19

    BurmanPBromanJEHettaJWiklundIErfurthEMHaggEKarlssonFA. Quality of life in adults with growth hormone (GH) deficiency: response to treatment with recombinant human GH in a placebo-controlled 21-month trial. Journal of Clinical Endocrinology and Metabolism 1995 3585–3590. (https://doi.org/10.1210/jcem.80.12.8530603)

    • Search Google Scholar
    • Export Citation
  • 20

    BollerslevJUelandTJørgensenAPFougnerKJWergelandRSchreinerTBurmanP. Positive effects of a physiological dose of GH on markers of atherogenesis: a placebo-controlled study in patients with adult-onset GH deficiency. European Journal of Endocrinology 2006 537–543. (https://doi.org/10.1530/eje.1.02125)

    • Search Google Scholar
    • Export Citation
  • 21

    FriedewaldWTLevyRIFredricksonDS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clinical Chemistry 1972 499–502.

    • Search Google Scholar
    • Export Citation
  • 22

    American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2013 (Supplement 1) S67–S74. (https://doi.org/10.2337/dc13-S067)

    • Search Google Scholar
    • Export Citation
  • 23

    GutiérrezLPKołtowska-HäggströmMJönssonPJMattssonAFSvenssonDWestbergBLugerA. Registries as a tool in evidence-based medicine: example of KIMS (Pfizer International Metabolic Database). Pharmacoepidemiology and Drug Safety 2008 90–102. (https://doi.org/10.1002/pds.1510)

    • Search Google Scholar
    • Export Citation
  • 24

    McKennaSPDowardLCAlonsoJKohlmannTNieroMPrietoLWirenL. The QoL-AGHDA: an instrument for the assessment of quality of life in adults with growth hormone deficiency. Quality of Life Research 1999 373–383. (https://doi.org/10.1023/A:1008987922774)

    • Search Google Scholar
    • Export Citation
  • 25

    FilipssonHMonsonJPKoltowska-HäggströmMMattssonAJohanssonG. The impact of glucocorticoid replacement regimens on metabolic outcome and comorbidity in hypopituitary patients. Journal of Clinical Endocrinology and Metabolism 2006 3954–3961. (https://doi.org/10.1210/jc.2006-0524)

    • Search Google Scholar
    • Export Citation
  • 26

    FleseriuMHashimIAKaravitakiNMelmedSMuradMHSalvatoriRSamuelsMH. Hormonal replacement in hypopituitarism in adults: an Endocrine Society clinical guideline. Journal of Clinical Endocrinology and Metabolism 2016 3888–3921. (https://doi.org/10.1210/jc.2016-2118)

    • Search Google Scholar
    • Export Citation
  • 27

    Feldt-RasmussenUKloseM. Central hypothyroidism and its role for cardiovascular risk factors in hypopituitary patients. Endocrine 2016 15–23. (https://doi.org/10.1007/s12020-016-1047-x)

    • Search Google Scholar
    • Export Citation
  • 28

    RossouwJEAndersonGLPrenticeRLLaCroixAZKooperbergCStefanickMLJacksonRDBeresfordSAHowardBVJohnsonKC et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA 2002 321–333. (https://doi.org/10.1001/jama.288.3.321)

    • Search Google Scholar
    • Export Citation
  • 29

    WeberMMBillerBMPedersenBTPournaraEChristiansenJSHöybyeC. The effect of growth hormone (GH) replacement on blood glucose homeostasis in adult nondiabetic patients with GH deficiency: real-life data from the NordiNet® International Outcome Study. Clinical Endocrinology 2017 192–198. (https://doi.org/10.1111/cen.13256)

    • Search Google Scholar
    • Export Citation
  • 30

    NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4.4 million participants. Lancet 2016 1513–1530. (https://doi.org/10.1016/S0140-6736(16)00618-8)

    • Search Google Scholar
    • Export Citation
  • 31

    World Health Organization. Global report on diabetes. (available at: http://apps.who.int/iris/bitstream/10665/204871/1/9789241565257_eng.pdf). Accessed on 9 July 2019.

    • Search Google Scholar
    • Export Citation